Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 1b clinical study titled ‘Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer.’ The study aims to assess the safety, tolerability, and feasibility of administering Xaluritamig before radical prostatectomy in patients with newly diagnosed localized intermediate or high-risk prostate cancer. This research is significant as it explores potential improvements in pre-surgical treatment options for prostate cancer.
The intervention being tested is Xaluritamig, an experimental drug administered via intravenous infusion. Its purpose is to evaluate its effectiveness and safety when used as a neoadjuvant therapy prior to surgery.
The study is designed as an interventional trial with a single-group assignment. It is non-randomized and open-label, meaning all participants receive the same treatment and both researchers and participants know what treatment is being administered. The primary aim is treatment-focused.
The study began on September 23, 2024, with the latest update submitted on July 24, 2025. These dates are crucial as they indicate the study’s progress and current status, which is still recruiting participants.
This update could positively influence Amgen’s stock performance by showcasing their commitment to innovative cancer treatments. It may also affect investor sentiment positively, given the potential advancements in prostate cancer therapy. Competitors in the oncology space will be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.